Bridgewater Associates LP Has $5.55 Million Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Bridgewater Associates LP grew its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 63.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 301,072 shares of the company's stock after acquiring an additional 117,251 shares during the quarter. Bridgewater Associates LP owned 0.14% of Hims & Hers Health worth $5,546,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Robeco Institutional Asset Management B.V. bought a new stake in Hims & Hers Health during the 3rd quarter worth approximately $604,000. Carnegie Investment Counsel bought a new stake in Hims & Hers Health during the 3rd quarter worth approximately $5,531,000. Royce & Associates LP increased its stake in Hims & Hers Health by 17.0% during the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company's stock worth $6,281,000 after purchasing an additional 49,500 shares in the last quarter. Versor Investments LP bought a new stake in Hims & Hers Health during the 3rd quarter worth approximately $634,000. Finally, International Assets Investment Management LLC bought a new stake in Hims & Hers Health during the 3rd quarter worth approximately $6,790,000. 63.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on HIMS. Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They issued a "buy" rating and a $24.00 target price for the company. Bank of America downgraded Hims & Hers Health from a "buy" rating to an "underperform" rating and decreased their price objective for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. TD Cowen restated a "buy" rating and issued a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Piper Sandler reaffirmed a "neutral" rating and set a $21.00 price target (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Finally, Imperial Capital downgraded shares of Hims & Hers Health from an "outperform" rating to an "in-line" rating in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $20.71.

Hims & Hers Health Stock Performance

NYSE:HIMS traded up $1.88 during mid-day trading on Friday, hitting $32.22. 10,258,617 shares of the stock were exchanged, compared to its average volume of 9,809,085. The firm's 50-day simple moving average is $22.01 and its 200 day simple moving average is $19.90. The stock has a market capitalization of $7.04 billion, a price-to-earnings ratio of 73.23 and a beta of 1.06. Hims & Hers Health, Inc. has a fifty-two week low of $8.09 and a fifty-two week high of $35.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same period last year, the firm earned ($0.04) earnings per share. Hims & Hers Health's revenue for the quarter was up 77.1% compared to the same quarter last year. On average, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In related news, Director Anja Manuel purchased 4,000 shares of the firm's stock in a transaction that occurred on Tuesday, November 12th. The shares were bought at an average cost of $26.94 per share, with a total value of $107,760.00. Following the acquisition, the director now owns 4,000 shares of the company's stock, valued at $107,760. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the firm's stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the sale, the chief executive officer now owns 33,502 shares in the company, valued at $487,789.12. This represents a 84.94 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,153,519 shares of company stock worth $24,486,721. Company insiders own 17.71% of the company's stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.